Want to see SHTDY full AI Analyst Report?
SHTDY Stock Chart & Stats
$10.08
<$0.01(0.07%)
At close: 4:00 PM EDT
$10.08
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$9.62 - $14.04
Previous CloseN/A
Volume67.41K
Average Volume (3M)26.32K
Market Cap
$6.11B
Enterprise Value$24.47K
Total Cash (Recent Filing)$41.90B
Total Debt (Recent Filing)$113.83B
Price to Earnings (P/E)5.7
Beta0.10
Next Earnings
Nov 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.22%
Share Statistics
EPS (TTM)11.15
Shares Outstanding268,362,150
10 Day Avg. Volume39,330
30 Day Avg. Volume26,316
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent conversion of earnings into operating and free cash flow supports internal funding capacity and reinforces the quality of reported profits. Although recent free cash flow weakened, the multi-year record provides a durable financial base for working capital and ongoing healthcare distribution activities.
Nationwide Distribution NetworkA nationwide healthcare distribution network provides broad access to institutional and retail customers across multiple channels. This reach supports recurring product flows, strengthens operating scale, and gives the company an established platform for distributing medicines, devices, diagnostics, and consumables.
Broad Healthcare Product MixExposure to several healthcare product categories reduces reliance on a single offering and allows the company to serve varied provider needs. Its combination of pharmaceuticals, devices, diagnostics, and consumables can support customer relevance and maintain distribution activity across healthcare settings.
Bears Say
Recent Revenue ContractionRecent revenue contraction indicates that the company’s core distribution activity has lost momentum after stronger growth in 2021–2023. If this persists, slower volume expansion would limit operating leverage, reduce investment capacity, and make it harder to offset pressure elsewhere in the business.
Margin CompressionLower gross and EBITDA margins show that profitability has become more constrained despite the company remaining profitable. Thin margins leave less room to absorb procurement, pricing, or operating pressure, while sustained compression could weaken earnings resilience and reduce returns on the distribution platform.
Higher Leverage And Lower ReturnsThe sharp increase in debt relative to equity raises financial risk and reduces flexibility compared with the prior year. Combined with lower return on equity, the change suggests capital is being used less efficiently, potentially constraining future investment and increasing sensitivity to weaker profitability.
Sinopharm Group Co News
SHTDY FAQ
What was Sinopharm Group Co’s price range in the past 12 months?
Sinopharm Group Co lowest stock price was $9.62 and its highest was $14.04 in the past 12 months.
What is Sinopharm Group Co’s market cap?
Sinopharm Group Co’s market cap is $6.11B.
When is Sinopharm Group Co’s upcoming earnings report date?
Sinopharm Group Co’s upcoming earnings report date is Nov 02, 2026 which is in 46 days.
How were Sinopharm Group Co’s earnings last quarter?
Sinopharm Group Co released its earnings results on Aug 23, 2026. The company reported $0.795 earnings per share for the quarter.
Is Sinopharm Group Co overvalued?
According to Wall Street analysts Sinopharm Group Co’s price is currently Overvalued.
Does Sinopharm Group Co pay dividends?
Sinopharm Group Co pays a Annually dividend of $0.503 which represents an annual dividend yield of 5.22%. See more information on Sinopharm Group Co dividends here
What is Sinopharm Group Co’s EPS estimate?
Sinopharm Group Co’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinopharm Group Co have?
Sinopharm Group Co has 268,362,150 shares outstanding.
What happened to Sinopharm Group Co’s price movement after its last earnings report?
Sinopharm Group Co reported an EPS of $0.795 in its last earnings report. Following the earnings report the stock price went up 0.102%.
Which hedge fund is a major shareholder of Sinopharm Group Co?
Currently, no hedge funds are holding shares in SHTDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinopharm Group Co Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.82%
12-Months-Change
Fundamentals
Return on Equity
5.22%
Trailing 12-Months
Asset Growth
1.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sinopharm Group Co
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pharmaceutical Distribution segment is responsible for supplying a wide array of pharmaceutical products to various healthcare entities, including hospitals, clinics, and retail pharmacies. This segment also provides comprehensive logistics and value-added services to both domestic and international manufacturers and suppliers of pharmaceutical and healthcare items. The Medical Devices segment focuses specifically on the distribution of medical equipment. Through its Retail Pharmacy segment, the company operates and franchises an extensive chain of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment encompasses the manufacturing and sale of pharmaceutical products, chemical reagents, and laboratory supplies. Beyond these core activities, Sinopharm Group also engages in property rental and management, distributes specialized products such as Chinese herbal medicines, antibiotics, and biological products, and offers a suite of services. These include IT development, medicine, business, health, and market information consulting, international trade (import/export of goods and technology), market investigation, and convention and exhibition services. Furthermore, the company is involved in medical project investment, consulting, and technology training. To enhance its commercial capabilities and transformation, Sinopharm Group Co. Ltd. maintains a strategic partnership with I-Mab. Founded in 2003, the company is headquartered in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.